Screener
Theravance Biopharma TBPH Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
| Provision for income tax benefit | 1,537 | 559 |
| Net loss | (4,933) | (13,579) |
| Net unrealized loss on available-for-sale investments | (123) | (7) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's other income (expense)?
- Theravance Biopharma (TBPH) reported other income (expense) of $3.01M in Q1 2026.
- How has Theravance Biopharma's other income (expense) changed year-over-year?
- Theravance Biopharma's other income (expense) increased by 220.9% year-over-year, from $939K to $3.01M.
- What is the long-term trend for Theravance Biopharma's other income (expense)?
- Over 4 years (2021 to 2025), Theravance Biopharma's other income (expense) has grown at a 74.0% compound annual growth rate (CAGR), from $1.11M to $10.17M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Theravance Biopharma's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude